好中球減少症治療の世界市場2020–2027:治療別(コロニー刺激因子、抗生物質、抗真菌薬、抗ウイルス薬)、流通経路別

◆英語タイトル:Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals, and Antivirals), and Distribution Channel (Hospital Pharmacies , Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:AMR20JL063
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年5月
◆ページ数:210
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥563,850見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥677,250見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥944,475見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、好中球減少症治療の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、治療別(コロニー刺激因子、抗生物質、抗真菌薬、抗ウイルス薬)分析、流通経路別分析、地域別分析、企業情報など、今後の市場展望をまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場動向
・好中球減少症治療の世界市場規模:治療別(コロニー刺激因子、抗生物質、抗真菌薬、抗ウイルス薬)
・好中球減少症治療の世界市場規模:流通経路別
・好中球減少症治療の世界市場規模:地域別
・企業情報
【レポートの概要】

The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.

Neutropenia refers to reduced neutrophil count in the blood. Normal individuals have a neutrophil count in the blood ranging between 1,500 and 8,000 cells/cubic meter. When neutrophil count falls below the 1,500 cells/mm3 threshold, a patient is classified as neutropenic. Generally, neutrophils drop below normal level within after 7-12 days of cancer chemotherapy.

The demand for neutropenia therapy is projected to experience substantial growth in the future, owing to growth in incidences of cancer cases. Increase in R&D activities by key companies to establish new neutropenia therapies are also anticipated to fuel the demand during the forecast period. However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period. In addition, paradigm transition from branded drugs to low-cost biosimilars is projected to provide industry players with remunerative incentives.

Depending on treatment, the market is categorized into colony-stimulating factors, antibiotics, antifungals, and antivirals. The colony-stimulating factors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Rise in incidences of cancer cases and further increase in number of patients undergoing chemotherapy around the globe drives the growth of this treatment segment.

On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
North America accounted for the largest share in the global neutropenia treatment market. Further, Asia-Pacific is expected to witness highest growth rate for the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period. As, Europe is considered as the advanced biosimilar market as compared to non-European countries, high cost of the treatment of neutropenia is expected to restrict the growth of the market during the forecast period.

The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.

KEY BENEFITS FOR STAKEHOLDERS

• This report entails a detailed quantitative analysis along with the current neutropenia treatment trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2020 to 2027.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Treatment
• Colony-stimulating factors,
• Antibiotics
• Antifungals
• Antivirals

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA

KEY MARKET PLAYERS
• Amgen
• BeyondSpring
• Kyowa Kirin
• Cellerant Therapeutics
• Mylan N.V.
• Novartis AG
• Partner Therapeutics
• Pfizer
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Coherus Biosciences

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Pipeline Analysis
3.2.2.Top winning strategies
3.2.3.Top player positioning

3.3.Key forces shaping the global neutropenia treatment market
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Rise in prevalence of leukemia
3.4.1.2.Surge in R&D efforts and development of new drugs
3.4.1.3.Fundamental shift from branded drugs to biosimilars in cancer supportive treatment

3.4.2.Restraints

3.4.2.1.High cost of the treatment of neutropenia
3.4.2.2.Stringent rules and regulations for product approvals

3.4.3.Opportunity

3.4.3.1.Robust drug pipeline for neutropenia treatment

3.5.Standard of Care for Neutropenia treatment and recommended guidelines

CHAPTER 4:GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT

4.1.Overview

4.1.1.Market size and forecast

4.2.Colony-stimulating factors (CSFs)

4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Antibiotics

4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Antifungals

4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antivirals

4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital Pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail Pharmacies

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online Pharmacies

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by treatment
6.2.3.Market size and forecast, by distribution channel
6.2.4.Market size and forecast, by country

6.2.4.1.U.S.
6.2.4.2.Purchasing/distribution channels in the U.S.

6.2.4.2.1.U.S. market size and forecast, by treatment
6.2.4.2.2.U.S. market size and forecast, by distribution channel

6.2.4.3.Canada

6.2.4.3.1.Canada market size and forecast, by treatment
6.2.4.3.2.Canada market size and forecast, by distribution channel

6.2.4.4.Mexico

6.2.4.4.1.Mexico market size and forecast, by treatment
6.2.4.4.2.Mexico market size and forecast, by distribution channel

6.3.Europe

6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by treatment
6.3.3.Market size and forecast, by distribution channel
6.3.4.Market size and forecast, by country

6.3.4.1.Purchasing/distribution channels in the Europe
6.3.4.2.Germany

6.3.4.2.1.Germany market size and forecast, by treatment
6.3.4.2.2.Germany market size and forecast, by distribution channel

6.3.4.3.France

6.3.4.3.1.France market size and forecast, by treatment
6.3.4.3.2.France market size and forecast, by distribution channel

6.3.4.4.UK

6.3.4.4.1.UK market size and forecast, by treatment
6.3.4.4.2.UK market size and forecast, by distribution channel

6.3.4.5.Italy

6.3.4.5.1.Italy market size and forecast, by treatment
6.3.4.5.2.Italy market size and forecast, by distribution channel

6.3.4.6.Spain

6.3.4.6.1.Spain market size and forecast, by treatment
6.3.4.6.2.Spain market size and forecast, by distribution channel

6.3.4.7.Rest of Europe

6.3.4.7.1.Rest of Europe market size and forecast, by treatment
6.3.4.7.2.Rest of Europe market size and forecast, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by treatment
6.4.3.Market size and forecast, by distribution channel
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Purchasing/distribution channels in the Japan
6.4.4.1.2.Japan market size and forecast, by treatment
6.4.4.1.3.Japan market size and forecast, by distribution channel

6.4.4.2.China

6.4.4.2.1.China market size and forecast, by treatment
6.4.4.2.2.China market size and forecast, by distribution channel

6.4.4.3.Australia

6.4.4.3.1.Australia market size and forecast, by treatment
6.4.4.3.2.Australia market size and forecast, by distribution channel

6.4.4.4.India

6.4.4.4.1.India market size and forecast, by treatment
6.4.4.4.2.India market size and forecast, by distribution channel

6.4.4.5.Rest of Asia-Pacific

6.4.4.5.1.Rest of Asia-Pacific market size and forecast, by treatment
6.4.4.5.2.Rest of Asia-Pacific market size and forecast, by distribution channel

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by treatment
6.5.3.Market size and forecast, by distribution channel
6.5.4.Market size and forecast, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil market size and forecast, by treatment
6.5.4.1.2.Brazil market size and forecast, by distribution channel

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia market size and forecast, by treatment
6.5.4.2.2.Saudi Arabia market size and forecast, by distribution channel

6.5.4.3.South Africa

6.5.4.3.1.South Africa market size and forecast, by treatment
6.5.4.3.2.South Africa market size and forecast, by distribution channel

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA market size and forecast, by treatment
6.5.4.4.2.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.AMGEN INC.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.BEYONDSPRING INC.

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments

7.3.CELLERANT THERAPEUTICS, INC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Key strategic moves and developments

7.4.KYOWA KIRIN

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.MYLAN N.V.

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.NOVARTIS AG

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.PARTNER THERAPEUTICS, INC.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Key strategic moves and developments

7.8.PFIZER INC.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.SPECTRUM PHARMACEUTICALS, INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance

7.11.COHERUS BIOSCIENCES, INC.

7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.11.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.DOSAGE AND ADMINISTRATION OF CSFS
TABLE 02.GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019–2027 ($MILLION)
TABLE 03.GLOBAL NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY REGION, 2019–2027($MILLION)
TABLE 04.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2019–2027($MILLION)
TABLE 05.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIFUNGAL, BY REGION, 2019–2027($MILLION)
TABLE 06.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY REGION, 2019–2027($MILLION)
TABLE 07.GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 08.GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019–2027($MILLION)
TABLE 09.GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2019–2027($MILLION)
TABLE 10.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2019–2027($MILLION)
TABLE 11.GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION 2019–2027, ($MILLION)
TABLE 12.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 13.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 14.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 15.U.S. NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 16.U.S. NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 17.CANADA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 18.CANADA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 19.MEXICO NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 20.MEXICO NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 21.EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 22.EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 23.EUROPE NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 24.GERMANY NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 25.GERMANY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 26.FRANCE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 27.FRANCE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 28.UK NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 29.UK NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 30.ITALY NEUTROPENIA TREATMENT MARKET, BY TREATMETN, 2019-2027, ($MILLION)
TABLE 31.ITALY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 32.SPAIN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 33.SPAIN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 34.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 35.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 36.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 37.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 38.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 39.JAPAN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 40.JAPAN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 41.CHINA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 42.CHINA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 43.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 44.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 45.INDIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 46.INDIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 47.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 49.LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 50.LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 51.LAMEA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 52.BRAZIL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 53.BRAZIL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 54.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 55.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 56.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 57.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 58.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 59.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
TABLE 60.AMGEN: COMPANY SNAPSHOT
TABLE 61.AMGEN: OPERATING SEGMENTS
TABLE 62.AMGEN: PRODUCT PORTFOLIO
TABLE 63.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64.BEYONDSPRING : COMPANY SNAPSHOT
TABLE 65.BEYONDSPRING : PRODUCT PORTFOLIO
TABLE 66.BEYONDSPRING : KEY STRATEGIC MOVES AND DEVELOPMENT
TABLE 67.CELLERANT THERAPEUTICS : COMPANY SNAPSHOT
TABLE 68.CELLERANT THERAPEUTICS : PRODUCT PORTFOLIO
TABLE 69.CELLERANT THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70.KYOWA KIRIN : COMPANY SNAPSHOT
TABLE 71.KYOWA KIRIN: OPERATING SEGMENTS
TABLE 72.KYOWA KIRIN : PRODUCT PORTFOLIO
TABLE 73.MYLAN: COMPANY SNAPSHOT
TABLE 74.MYLAN: OPERATING SEGMENTS
TABLE 75.MYLAN: PRODUCT PORTFOLIO
TABLE 76.MYLAN : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.NOVARTIS: COMPANY SNAPSHOT
TABLE 78.NOVARTIS: OPERATING SEGMENTS
TABLE 79.NOVARTIS: PRODUCT PORTFOLIO
TABLE 80.PARTNER THERAPEUTICS : COMPANY SNAPSHOT
TABLE 81.PARTNER THERAPEUTICS : PRODUCT PORTFOLIO
TABLE 82.PARTNER THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83.PFIZER : COMPANY SNAPSHOT
TABLE 84.PFIZER : OPERATING SEGMENTS
TABLE 85.PFIZER : PRODUCT PORTFOLIO
TABLE 86.PFIZER : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.SPECTRUM PHARMACEUTICALS : COMPANY SNAPSHOT
TABLE 88.SPECTRUM PHARMACEUTICALS : OPERATING SEGMENTS
TABLE 89.SPECTRUM PHARMACEUTICALS : PRODUCT PORTFOLIO
TABLE 90.TEVA: COMPANY SNAPSHOT
TABLE 91.TEVA: OPERATING SEGMENTS
TABLE 92.TEVA: PRODUCT PORTFOLIO
TABLE 93.COHERUS BIOSCIENCES: COMPANY SNAPSHOT
TABLE 94.COHERUS BIOSCIENCES : OPERATING SEGMENTS
TABLE 95.COHERUS BIOSCIENCES: PRODUCT PORTFOLIO



LIST OF FIGURES

FIGURE 01.SEGMENTATION OF GLOBAL NEUTROPENIA TREATMENT MARKET
FIGURE 02.PIPELINE ANALYSIS, BY COUNTRY
FIGURE 03.PIPELINE ANALYSIS, BY PHASES
FIGURE 04.PIPELINE ANALYSIS, BY YEAR
FIGURE 05.TOP WINNING STRATEGIES, BY YEAR
FIGURE 06.TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 07.TOP WINNING STRATEGIES, BY COMPANY
FIGURE 08.TOP PLAYER POSTIONING, 2019
FIGURE 09.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 10.LOW BARGAINING POWER OF BUYERS
FIGURE 11.MODERATE THREAT OF SUBSTITUTION
FIGURE 12.MODERATE THREAT OF NEW ENTRANT
FIGURE 13.MODERATE COMPETITIVE RIVALRY
FIGURE 14.GLOBAL NEUTROPENIA TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA MARKET FOR ANTIFUNGAL, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.U.S. NEUTROPENIA MARKET, 2020–2027 ($MILLION)
FIGURE 23.AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.AMGEN : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 25.KYOWA KIRIN : NET SALES, 2017–2019 ($MILLION)
FIGURE 26.KYOWA KIRIN : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 27.KYOWA KIRIN : REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 28.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 30.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 32.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.PFIZER : NET SALES, 2017–2019 ($MILLION)
FIGURE 34.PFIZER : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.SPECTRUM PHARMACEUTICALS : NET SALES, 2016–2018 ($MILLION)
FIGURE 37.SPECTRUM PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 38.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 40.COHERUS BIOSCIENCES : NET SALES, 2017–2019 ($MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[好中球減少症治療の世界市場2020–2027:治療別(コロニー刺激因子、抗生物質、抗真菌薬、抗ウイルス薬)、流通経路別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆